Password Protected
To view this protected post, enter the password below:
Vivian Liu currently serves as Head of Corporate Affairs for PREMIA Holdings (HK) Limited, a developer of clinical-genomic oncology databases and service provider to pharmaceutical companies seeking to operate clinical trials throughout Asia. Prior to joining PREMIA, Vivian served in various roles, including as a member of Board of Directors and President, Chief Executive Officer and Chief Financial Officer for Innovus Pharmaceuticals, Inc., a publicly listed consumer healthcare company acquired by Aytu BioPharma in February 2020. Prior to Innovus, she served as the President and Chief Executive Officer of FasTrack Pharmaceuticals, Inc. From 2017-2018, she served as the Chief Operating Officer and a member of the Board of Directors of ThermoGenesis’ predecessor company, Cesca Therapeutics, Inc. Previously, Vivian served as Managing Director of OxOnc Services Company, an oncology development company, and prior to that, Ms. Liu co-founded and served as President, Chief Executive Officer, and board director of NexMed, Inc., a drug development company which was later renamed Apricus BioSciences. Prior to her appointment as President of NexMed, Ms. Liu served in several executive capacities, including as Executive Vice President, Chief Operating Officer, Chief Financial Officer and Vice President of Corporate Affairs. Ms. Liu has an M.P.A. from the University of Southern California and a B.A. from the University of California, Berkeley.
Mr. Selhorn has served as our Executive Vice President, Finance and Business Optimization since November 2022. Prior to this, Mr. Selhorn served as our Senior Vice President, Finance & Operations, Consumer Healthcare Division from February 2022 to November 2022 and as our Vice President, Finance, Consumer Healthcare Division from February 2020 to February 2022. Mr. Selhorn served as Vice President & Chief Financial Officer from April 2018 at Innovus Pharmaceuticals, Inc., a publicly held consumer healthcare company, until Aytu’s acquisition of Innovus in February 2020. From August 2013 to April 2018, Mr. Selhorn served as Chief Financial Officer and Chief Accounting Officer of Signature Analytics, a privately held fractional CFO and accounting firm, where he also served as Chief Financial Officer of Medicinova Inc, a publicly held biotechnology company, assisted Dare Bioscience, Inc. to complete a reverse merger into a publicly held entity, and worked with numerous other companies in the biotechnology industry as well as various other industries. Prior to this, Mr. Selhorn worked at Grant Thornton LLP, a public accounting firm, from October 2003 to July 2013, most recently in the role of Senior Manager, Transaction Advisory Services. Mr. Selhorn received his BSBA, Accounting and Finance from Georgetown University.
Victoria Cordova is our Vice President of People & Culture, aligning the company’s talent strategy with the needs of the business to help Aytu BioPharma grow and employees thrive. Victoria leads the company’s Human Resource initiatives in this role, including compensation, benefits and well-being, talent acquisition, learning and leadership development, culture, and employee relations. She is a member of Aytu’s executive team.
Victoria has over 20 years of Human Resource experience, including over 14 years in leadership roles. Before joining Aytu, Victoria held several Human Resources Executive Positions in various industries, including pharmacy, medical, and manufacturing, supporting growing organizations in locations in the U.S. and internationally. Victoria holds a Master of Business Administration with an emphasis in Global Management from the University of Phoenix.
Josh Disbrow has been in the life sciences industry for over twenty-five years across pharmaceuticals, diagnostics, and medical devices. Josh co-founded Aytu BioPharma in 2015 and took the company public, having led Aytu’s listing on NASDAQ in 2017. Prior to co-founding Aytu, Josh served as the Chief Operating Officer of Ampio Pharmaceuticals (NYSE MKT: AMPE), a clinical-stage biotechnology company developing anti-inflammatory biological therapies. Prior to joining Ampio in 2012, he served as Vice President of Commercial Operations at Arbor Pharmaceuticals, a private specialty pharmaceutical company.
Josh joined Arbor Pharmaceuticals as the second full-time employee and oversaw the launch and subsequent scaling of the company’s commercial operations. Josh led the commercial organization since the company’s inception and led the launch of the company’s first product, subsequently launching numerous products and scaling the commercial organization across sales, marketing, managed care, sales training, and national accounts. In less than five years, Arbor grew from the pre-commercialization stage to generating over $250 million in revenue.
Prior to joining Arbor, he served as the Director of Marketing at LipoScience (NASDAQ: LPDX), a specialty cardiovascular diagnostic company later acquired by LabCorp (NYSE: LH). Previously, Josh was in sales leadership at Cyberonics (Now LivaNova plc, NASDAQ: LIVN), a medical device company commercializing implantable neuromodulation devices.
Josh began his career as a sales representative at Glaxo Wellcome (now GlaxoSmithKline plc). Josh currently sits on the Board of Directors and is the Chair of the Nominating and Governance Committee of Zynex, Inc. (NASDAQ: ZYXI), a medical device company focused on electrotherapy and pain management. He holds a Bachelor of Science in Management and graduated with honors from North Carolina State University and received a Master of Business Administration from Wake Forest University.
Jarrett Disbrow is a seasoned pharmaceutical entrepreneur having been the founder of three pharmaceutical and life sciences companies over the past decade, with broad industry experience spanning over twenty years.
Most recently, and prior to forming Aytu BioPharma in April 2015, Jarrett was the President & CEO of Vyrix Pharmaceuticals, a specialty pharmaceutical company focused on male sexual dysfunction. Mr. Disbrow’s first pharmaceutical start-up was Arbor Pharmaceuticals, a company focused initially on pediatrics. As the sole founder of Arbor, Jarrett was responsible for the vision, fundraising, start-up, strategy and growth of the company until the acquisition by an investor group in 2010. Prior to founding Arbor Pharmaceuticals, he was head of marketing for Accentia Biopharmaceuticals, Inc. Jarrett began his career with GlaxoWellcome (now GlaxoSmithKline plc) where he held various roles in sales and marketing. He received a B.S. in Business Management from North Carolina State University in Raleigh, NC.
Prior to joining Aytu BioPharma at the closing of the company’s merger with Neos Therapeutics in March 2021, Greg Pyszczymuka served as Vice President, Commercial at Neos Therapeutics since June 2020. He previously served as Vice President, Commercial Strategy & Market Access at Neos from November 2018 to June 2020 and as Executive Director of Channel Strategy & Access Programs. Prior to joining Neos, Greg has served in roles of increasing responsibility over a 15-year career including sales management, brand management, channel strategy, managed markets and new products planning. Greg joined Neos most recently from Aqua Pharmaceuticals (an Almirall company) and previously was with Iroko Pharmaceuticals, Zogenix, and Endo Pharmaceuticals. He holds a B.S. from Rutgers University and an M.B.A. from Argosy University.
Topher Brooke joined the Aytu BioPharma executive team in April 2021 upon the acquisition of the global license to AR101 (enzastaurin) from Rumpus Therapeutics. Topher has over 20 years of general management experience in healthcare across all phases of development and commercialization. He has depth of experience from target selection and clinical development planning through running several blockbuster commercial pharmaceutical franchises. He has worked across several modalities (proteins, small molecules and vaccines) and across multiple therapeutic areas. Topher has held roles of increasing responsibility at Johnson & Johnson, AstraZeneca, and AmerisourceBergen. His rare disease experience includes launching pediatric inflammatory bowel disease indications while at Johnson & Johnson as well as leading the pediatric infectious disease franchise at AstraZeneca. Topher went on to lead the fully integrated Diabetes Division at AstraZeneca. Most recently, Topher co-founded Rumpus Therapeutics to develop new medicines for pediatric onset rare and orphan diseases. Topher has a BA from Colgate University and an MBA from the Wharton School at the University of Pennsylvania.
Russ McMahen has 30 years of industry experience specializing in the development of solid, liquid and suspension dosage forms. Mr. McMahen is the co-inventor of the DTRS® and RDIM™ ion exchange delivery technologies that were utilized to develop the modified release microparticles that are used in Aytu BioPharma’s products. Prior to joining Aytu BioPharma upon the merger with Neos Therapeutics in 2021, Mr. McMahen held various positions including Senior Vice President, Research & Development, Executive Vice President of Operations and Vice President of Scientific Affairs. Prior to joining Neos, Mr. McMahen served at Zenith/Goldline Laboratories which was subsequently acquired by Ivax Pharmaceuticals. He has a B.S. in Chemical Engineering from Louisiana Tech University.
Margaret Cabano has served as the Vice President of Operations for Aytu BioPharma since the merger of Aytu BioScience and Neos Therapeutics in 2021. Ms. Cabano held the same role for Neos Therapeutics since 2005. She has 21 years of industry experience and leads all aspects of manufacturing operations, including supply chain, engineering, and technical services. Prior to joining Neos, Ms. Cabano worked in operations and supply chain management for Adams Respiratory Therapeutics and Cardinal Health. Ms. Cabano holds an M.B.A. in Operations Management Science and a B.A. in Supply Chain Logistics from the University of North Texas.
Suzane Kennedy is an experienced Regulatory Affairs and Quality Assurance leader in the life sciences industry. She has worked over 20 years across pharmaceuticals, dietary supplements, and medical devices. Most recently and prior to joining Aytu BioPharma in June 2018, Suzane was the Director of Quality Assurance with a start-up bioscience company, Armis Biopharma that focused on a combination product coming to market. Suzane started her career as a Quality Control Chemist at Upsher-Smith Laboratories and was promoted quickly into a management role. In order to continue her growth in the life science’s field Suzane moved into the medical device regulatory, including roles with ConMed Corporation and Cochlear Americas. She received a B.S. in Chemistry at Metro State University in Denver, Colorado.
Mr. Boyd is the Founder and Chief Investment Officer of Armistice Capital, a healthcare equity hedge fund he founded in 2012. Prior to founding Armistice, Mr. Boyd was a Research Analyst at Senator Investment Group, York Capital, and SAB Capital Management, where he focused on healthcare. Mr. Boyd began his career as an Analyst at McKinsey & Company.
Mr. Boyd has served as a member of the board of directors of Cerecor (NASDAQ: CERC), an integrated biopharmaceutical company focused on pediatric healthcare, since April 2017 and EyeGate Pharmaceuticals (NASDAQ: EYEG), a clinical-stage, specialty pharmaceutical company focused on disorders of the eye, since May 2018. Mr. Boyd received a B.S. in Economics and a B.A. in Political Science from The Wharton School of the University of Pennsylvania.
He was also president of the Catevo Group, a North Carolina-based healthcare consulting firm, and Executive Vice President, Sales and Marketing at TEAMM Pharmaceuticals, an Accentia Biopharmaceuticals company. Mr. Cantrell started his pharmaceutical career at GSK, where he held multiple senior management positions in sales, marketing and business development over a period of 22 years. Gary serves on the Compensation Committee and Nominating & Governance Committee. He has served as an advisor or board member of several emerging life science companies including his previous role as a board member at Flexible Stenting Solutions, Inc., which was sold to Cordis, while a division of Johnson & Johnson in March 2013. Mr. Cantrell is a graduate of Wichita State University.
Carl Dockery is a financial executive with many years of experience in the insurance and reinsurance industry and more recently in 2006 as the founder of a registered investment advisory firm, Alpha Advisors, LLC. Carl’s 20-year career as an insurance executive began in 1988 as an officer and director of two related and closely held insurance companies, including serving as secretary of Crossroads Insurance Co. Ltd. of Bermuda and as Vice President of Gulf Insurance Co. Ltd. of Grand Cayman.
Familiar with the London reinsurance market, in the 1990s, Mr. Dockery worked at Lloyd’s and the London Underwriting Centre brokering various types of reinsurance placements. Carl is the Chair of Aytu’s Nominating & Governance Committee and serves on the Compensation Committee and Audit Committee. Carl was formerly a member of the Board of Directors of CytoDyn, Inc., a publicly traded biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of Human Immunodeficiency Virus (HIV) infection and is an active investor in various healthcare companies through Alpha Ventures, the venture capital affiliate of Alpha Advisors. Mr. Dockery graduated from Southeastern University with a Bachelor of Arts in Humanities.
John Donofrio serves as the Chief Operating Officer of Novan, Inc. (Nasdaq: NOVN) and President of EPI Health subsidiary following EPI Health’s acquisition by Novan in 2022. He has over 30 years of experience in leading US and International teams in the pharmaceutical industry and brings a proven track record of business, operations, strategic, and financial leadership. Prior to EPI, Mr. Donofrio was CFO at TrialCard, and earlier was CFO and Head of Business Development for Merz North America. In addition to his executive positions, Mr. Donofrio spent over 20 years with GSK in various US and international roles, including Global Vice President of finance for the dermatology business unit, Stiefel, a GSK company. John is the Chair of Aytu’s Audit Committee and a member of the Nominating and Governance Committee and the Compensation Committee. He also serves on the board of directors of the Children’s Skin Disease Foundation and Alliance Medical Ministries. Mr. Donofrio is a graduate of North Carolina State University, with a degree in accounting.
Abhinav “Abi” Jain is an Analyst at Nantahala Capital Management and is focused on investments in various sectors, including specialty and generic pharmaceuticals. Prior to joining Nantahala in 2019, Mr. Jain was an Associate at Angelo, Gordon & Co., an alternative asset manager based in New York from 2015-2017. At Angelo, Gordon & Co., Mr. Jain focused on private equity and structured credit investments. He graduated from Massachusetts Institute of Technology in 2012 with an S.B. in Chemical-Biological Engineering and from The Wharton School of the University of Pennsylvania in 2019 with an M.B.A. with honors in Finance and Entrepreneurial Management.